BXCL701
BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
What will happen during the trial?
This is a multi-center, single-arm, Phase I research study for the study drug, BXCL701, for participants with refractory or relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome with Excess Blasts-2 (MDS-EB-2). Phase I clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means the drug is being studied. BXCL701 is a synthetic dipeptide that is in tablet form and is taken by mouth.
The U.S. Food and Drug Administration (FDA) has not approved BXCL701 as a treatment for any disease.
Research study procedures include screening for eligibility and study treatment including evaluations, blood collections, bone marrow biopsies, and follow up visits.
Participation in this study will last approximately 3 years.
It is expected that about 24 people will participate in this study.
BioXcel is supporting this research study by providing the study drug and funding research tests and procedures.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 24 patients (estimated)
- Sponsors
- Dana-Farber Cancer Institute
- Tags
- Dipeptidyl Peptidase 4 (DPP-4) Inhibitor
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 1488
- NCT Identifier
- NCT05703542
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.